- Report
- November 2023
- 141 Pages
Global
From €2414EUR$2,499USD£2,065GBP
- Report
- March 2024
- 196 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 194 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 192 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- February 2024
- 78 Pages
Global
From €3380EUR$3,500USD£2,893GBP
- Report
- February 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- July 2023
- 220 Pages
Global
From €1922EUR$1,990USD£1,645GBP
- Report
- February 2024
- 110 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2897EUR$3,000USD£2,479GBP
- Report
- November 2023
- 30 Pages
Global
From €2656EUR$2,750USD£2,273GBP
- Report
- April 2024
- 187 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- October 2023
- 190 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- November 2023
- 144 Pages
Global
From €4298EUR$4,450USD£3,678GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4588EUR$4,750USD£3,926GBP
- Report
- February 2024
- 112 Pages
Middle East, Africa
From €4588EUR$4,750USD£3,926GBP
- Report
- August 2022
- 120 Pages
Global
From €5312EUR$5,500USD£4,546GBP
- Report
- July 2022
- 150 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- March 2022
- 140 Pages
Global
From €1922EUR$1,990USD£1,645GBP
- Report
- February 2023
- 120 Pages
Israel
From €2405EUR$2,490USD£2,058GBP
From €3380EUR$3,500USD£2,893GBP
Rapid Acting Insulin is a type of insulin used to treat endocrine and metabolic disorders. It is a short-acting insulin that is injected before meals to help control blood sugar levels. It works quickly to lower blood sugar levels and can be used in combination with other types of insulin. Rapid Acting Insulin is typically used to treat type 1 diabetes, but can also be used to treat type 2 diabetes. It is important to monitor blood sugar levels closely when using Rapid Acting Insulin, as it can cause hypoglycemia if taken in too high of a dose.
Rapid Acting Insulin is available in both injectable and inhaled forms. Injectable forms include regular insulin, lispro, aspart, and glulisine. Inhaled forms include Afrezza and Admelog. These forms of insulin are designed to work quickly and provide a more convenient way to manage blood sugar levels.
Some companies in the Rapid Acting Insulin market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. These companies produce a variety of Rapid Acting Insulin products, including injectable and inhaled forms. Show Less Read more